Assessment of Disease Severity, Progression and Treatment in Infected Patients Presenting to the Emergency Department

CompletedOBSERVATIONAL
Enrollment

684

Participants

Timeline

Start Date

March 15, 2018

Primary Completion Date

August 31, 2018

Study Completion Date

August 31, 2018

Conditions
Sepsis
Interventions
DIAGNOSTIC_TEST

Measurement of MR-proADM

It is an observational study. The only intervention was the measure of MR-proADM, but no clinical decision was made based on its value, since the physician attending the patient did´n know the value of MR-proADM

Trial Locations (3)

28040

Hospita Clínico San Carlos, Madrid

03010

Hospital Universitario General de Alicante, Alicante

08907

Hospital Universitario de Bellvitge, Barcelona

All Listed Sponsors
collaborator

Thermo Fisher Scientific, Inc

INDUSTRY

lead

Juan González-del Castillo

OTHER

NCT03992794 - Assessment of Disease Severity, Progression and Treatment in Infected Patients Presenting to the Emergency Department | Biotech Hunter | Biotech Hunter